Sofinnova Partners, a European venture capital firm specialized in Life Sciences, appointed Antoine Papiernik as Chairman.
Papiernik, who succeeds Denis Lucquin who remains as a Managing Partner, joined Sofinnova Partners in 1997. He has a track record investing in companies that have gone on to be publicly listed on international exchanges or been acquired by leading players in the sector.
Papiernik has been the lead investor in public companies like Actelion, ProQR, NovusPharma, Movetis, Mainstay, Pixium Vision and Stentys which have listed on a wide range of exchanges including the Zürich stock exchange, NASDAQ, Milan’s Nuovo Mercato, Euronext Brussels, the Dublin stock exchange and Euronext Paris.
He was also the lead investor at inception of CoreValve (sold to Medtronic), Fovea (sold to Sanofi) and Ethical Oncology Science (sold to Clovis Oncology).
Papiernik is currently the lead investor and sits on the Board of Gecko Biomedical, MD Start, Shockwave Medical, Rgenix, Corwave, and Reflexion Medical.
FinSMEs
28/03/2017